Skip to main content
. 2020 Jan 17;2020:1924379. doi: 10.1155/2020/1924379

Table 1.

Treatment and challenge of CAR-T cell therapy in the treatment of solid tumors.

Clinical challenges Strategy Expected outcome
Lack of specific targets [44] Designed an antigen-specific inhibitory CAR-T molecule and a dual target CAR-T cells [48, 94] Achieving dynamic and safe regulation of CAR-T cells [49]
CAR-T cell cannot effectively migrate and infiltrate tumor tissue [44] Overexpression of HPSE in CAR-T cells can effectively degrade extracellular matrix and effectively infiltrate tumor tissue Applied to solid tumor treatment [94]
Effect of tumor microenvironment on CAR-T cell therapy [44] Specific blocking of immune checkpoint inhibition [48, 49, 94] Improving the therapeutic effect of CAR-T cells in solid tumor [48, 94]
Tumor heterogeneity [52] Expanding the scope of CAR-T cell therapy targeting tumor cells Reduce tumor cells to immune response without immune response or low response to immune escape